News | April 03, 2026
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
This marks a meaningful step in the company's continued expansion in the region
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Subscribe To Our Newsletter & Stay Updated
